ATLANTA, GA – – (Newsfile Corp. – August 25, 2021) – – Holzer & Holzer, LLC is investigating whether Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA) complied with federal securities laws. On August 24, 2021, it was revealed that a Citizen Petition had been filed with the FDA, questioning the quality and integrity of the Company’s research and data, suggesting the data had been manipulated. The Petition further sought a halt to Cassava’s current clinical studies of Simufilam. On this news, the price of the Company’s stock plummeted. If you purchased Cassava stock and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at email@example.com or Joshua Karr, Esq. at firstname.lastname@example.org, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com to discuss your legal rights.